The agreement calls for Medtronic to make an upfront cash payment of $800 million, plus commercial milestones equal to the annual revenue growth through the end of Medtronic’s fiscal year 2015. Medtronic had previously invested in Ardian and currently holds an 11% ownership stake in the Company. Based in Mountain View, California, Ardian develops catheter-based therapies to treat hypertension and related conditions.
The agreement calls for Medtronic to make an upfront cash payment of $800 million, plus commercial milestones equal to the annual revenue growth through the end of Medtronic’s fiscal year 2015. Medtronic had previously invested in Ardian and currently holds an 11% ownership stake in the Company. Based in Mountain View, California. Ardian develops catheter-based therapies to treat hypertension and related conditions.
“Hypertension is the leading attributable cause of death worldwide. It is a significant, escalating global healthcare problem affecting approximately 1.2 billion people and is associated with an increased risk of heart attack, stroke, heart failure, kidney disease and death,” said Sean Salmon, vice president and general manager of the Coronary and Peripheral Business at Medtronic. “We view renal denervation for the treatment of uncontrolled hypertension as one of the most exciting growth markets in medical devices. Ardian’s investigational catheter-based treatment for uncontrolled hypertension through renal nerve denervation complements Medtronic’s expertise in catheter design and ablation technologies, and augments Medtronic’s interventional therapies.”
Data from a clinical study of Ardian’s flagship product, the Symplicity Catheter System, were recently released at the American Heart Association 2010 Scientific Sessions in Chicago and published in The Lancet. It was reported that patients treated with the Ardian device experienced a 33 mmHg greater reduction in systolic blood pressure at six months (p<0.0001) than the control group. The Symplicity Catheter System has received CE mark and Australia TGA listing, but is not approved for sale in the USA.
“Ardian brings to Medtronic the Symplicity Catheter System and a growing body of evidence to support its clinical use for patients whose hypertension remains uncontrolled despite optimal medical management,” said Andrew Cleeland, president and CEO of Ardian. “Our integration into Medtronic creates a tremendous opportunity to leverage Medtronic’s global scale and scope to advance the treatment of uncontrolled hypertension.”
The transaction is expected to close in Medtronic’s third fiscal quarter of 2011, and is subject to customary closing conditions, including USA and foreign regulatory clearances.
“Hypertension is the leading attributable cause of death worldwide. It is a significant, escalating global healthcare problem affecting approximately 1.2 billion people and is associated with an increased risk of heart attack, stroke, heart failure, kidney disease and death,” said Sean Salmon, vice president and general manager of the Coronary and Peripheral Business at Medtronic. “We view renal denervation for the treatment of uncontrolled hypertension as one of the most exciting growth markets in medical devices. Ardian’s investigational catheter-based treatment for uncontrolled hypertension through renal nerve denervation complements Medtronic’s expertise in catheter design and ablation technologies, and augments Medtronic’s interventional therapies.”
Data from a clinical study of Ardian’s flagship product, the Symplicity Catheter System, were recently released at the American Heart Association 2010 Scientific Sessions in Chicago and published in The Lancet. It was reported that patients treated with the Ardian device experienced a 33 mmHg greater reduction in systolic blood pressure at six months (p<0.0001) than the control group. The Symplicity Catheter System has received CE mark and Australia TGA listing, but is not approved for sale in the USA.
“Ardian brings to Medtronic the Symplicity Catheter System and a growing body of evidence to support its clinical use for patients whose hypertension remains uncontrolled despite optimal medical management,” said Andrew Cleeland, president and CEO of Ardian. “Our integration into Medtronic creates a tremendous opportunity to leverage Medtronic’s global scale and scope to advance the treatment of uncontrolled hypertension.”
The transaction is expected to close in Medtronic’s third fiscal quarter of 2011, and is subject to customary closing conditions, including USA and foreign regulatory clearances.
